Many effective drugs that are already developed will not reach patients for years because the clinical trial system is the primary bottleneck. This delay is due to logistical and structural inefficiencies in testing, not a lack of scientific discovery.

There is no inherent conflict between speed and quality. High-quality studies prevent costly setbacks and generate reliable data, ultimately accelerating research programs. A low-quality study is what truly delays timelines by producing unusable or misleading results.

Drug developers often operate under a hyper-conservative perception of FDA requirements, avoiding novel approaches even when regulators might encourage them. This anticipatory compliance, driven by risk aversion, becomes a greater constraint than the regulations themselves, slowing down innovation and increasing costs.

Liz Parrish admits she might have given up if not for intense and often inaccurate media scrutiny. Instead of discouraging her, the criticism fueled her determination to push forward and prove her controversial approach to gene therapy was valid.

Parrish suggests that when analyzing criticism from the scientific community, one must consider financial motives. A researcher's funding and career are built on perpetuating research, not on translating it into real-world application, creating an inherent bias against moving too quickly.

Our ability to generate and test therapeutic hypotheses in silico is rapidly outpacing the slow, expensive conventional clinical trial system. Without regulatory reform, the pipeline of promising drugs will remain stuck, preventing breakthroughs from reaching patients. The science is solvable; the system is not.

Parrish explains her company was born from both science and the profound grief of witnessing her son's illness and the suffering in children's hospitals. This emotional impetus drove her to pursue unconventional and radical medical solutions, framing grief as a powerful catalyst for innovation.

Author and Ovid Therapeutics Chairman Jeremy Levin identifies a dangerous paradox: while biotech science is advancing at an extraordinary rate, the system that translates science into medicine is weakening. He points to pressures on capital, regulators, and public trust as fractures in the infrastructure that made American biotech dominant.

Parrish criticizes the celebration of marginal improvements in treatments, like an Alzheimer's drug with 2% efficacy. She argues this incrementalism isn't due to scientific limitations but is a business strategy based on patenting minor changes, while more effective gene therapies are often shelved.